Lipocine Inc.

LPCNReported to SECin USCIK 0001535955Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 4 rows. Everything we currently hold fits inside that, so nothing is being held back here today. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

Filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

4
Form 4 lines at Lipocine Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Higuchi John W.—Open-market buy$35,61315,970 sharesOct 1, 2026Higuchi John W.$35,613Buy · Oct 1Open-market buy15,970Oct 1, 2026
Higuchi John W.—Open-market buy$19,4309,037 sharesOct 1, 2026Higuchi John W.$19,430Buy · Oct 1Open-market buy9,037Oct 1, 2026
Higuchi John W.—Open-market buy$27,13212,561 sharesSep 30, 2026Higuchi John W.$27,132Buy · Sep 30Open-market buy12,561Sep 30, 2026
Grissinger Michael—Award$4,2202,000 sharesAug 7, 2026Grissinger Michael$4,220Award · Aug 7Award2,000Aug 7, 2026